The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지

Peripheral nitric oxide activity in patients with liver cirrhosis

간경변증 환자에서 말초혈액 Nitric Oxide 활성도 측정의 의의

Lee, Bo-Han;Baik, Du-San;Yun, Seoung-Ug;Shin, Jae-Min;Kim, Ji-Hwan;Yun, Se-Young;Kim, Byung-Ha;Kim, Suk-Bae;Shin, Jeong-Eun;Song, Il-Han
이보한;백두산;윤승욱;신재민;김지환;윤세영;김병하;김석배;신정은;송일한

  • Published : 20070900
⟨ Previous Next ⟩

Abstract

Background : Nitric Oxide (NO) induced by NO synthase is known to be associated with hyperdynamic circulation and collateralization by vascular remodeling in patients with cirrhosis. Methods : To assess the significance of peripheral NO activity in patients with cirrhosis, we measured the production of NO metabolites, nitrate and nitrite, using the nitrate/nitrite colorimetric assay with Griess reagents in the peripheral venous blood of 95 cirrhotic patients with or without clinical portal hypertension (PHT), and in the peripheral venous blood of 32 control patients without liver disease. Results : The peripheral NO activities in cirrhotic patients with clinical PHT, cirrhotic patients without clinical PHT, and non-liver disease control patients were 86.1±40.6 μmol/L, 83.5±47.2 μmol/L and 52.3±38.4 μmol/L, respectively. NO activity was significantly higher in cirrhotic patients than in non-liver disease control patients (p<0.05), while there was no significant difference of NO activity between the cirrhotic patients with or without clinical PHT. Peripheral NO activities in cirrhotic patients with Child-Pugh classification A, B, and C were 84.9±45.5 μmol/L, 81.9±53.2 μmol/L and 86.4±39.8 μmol/L, respectively; these results were not significantly different. A significant correlation of NO activity with the biochemical profiles of the serum albumin level, bilirubin level and prothrombin time were not defined. Conclusions : Peripheral NO activity was increased in cirrhotic patients, but it did not reflect the degree of clinical portal hypertension and the function of the hepatic reserve in this study. For a precise analysis of the association of NO and hyperdynamic circulation with collateralization in cirrhosis, intrahepatic or portal NO activity might be considered rather than peripheral NO activity.

목적 : Nitric oxide (NO)는 간경변증 환자에서 혈관 리모델링과 맥관형성에 의한 문맥 순환의 재분배를 통해 과역동 혈액순환를 초래하는 혈관이완제 중의 하나로 nitric oxide synthase (NOS)에 의해 유도된다. 간경변증에서 NO는 간내 순환계, 문맥과 내장 순환계 및 전신 순환계 등 유래하는 위치에 따라 그 활성도에 다소의 차이가 있는 것으로 알려져 있다. 본 연구에서는 간경변증 환자의 말초혈액에서 NO의 활성도를 측정하여 간기능 이상이 없는 대조군과 비교하고, 문맥압 항진증과 관련된 과역동 혈액순환 및 잔여 간기능에 따른 NO의 활성도를 비교분석하여 간경변증에서 비교적 쉽게 접근할 수 있는 말초혈액에서의 NO 활성도 측정의 의의를 알아보고자 하였다. 방법 : 2004년 3월부터 2005년 2월까지 본원에 내원한 환자 중 임상적으로 의미있는 문맥압 항진증의 합병증이 동반된 61명의 간경변증 환자와 동반되지 않은 34명의 간경변증 환자를 대상으로 하였으며 32명의 건강 검진자를 대조군으로 하였다. NO 활성도는 Griess 시약을 이용한 Nitrate/Nitrite Colorimetric Assay Kit(Cayman Chemical Co., Ann Arbor, USA)를 이용하여 대상 환자들의 말초혈액에서 측정하였다. 결과 : 간경변증 환자에서의 말초혈액 NO 활성도는 임상적 문맥압 항진증이 동반된 경우에 86.1±40.6 μmol/L, 동반되지 않은 경우에 83.5±47.2 μmol/L로 측정되어 대조군에서의 52.3±38.4 μmol/L에 비해 의미있게 높았으나(p<0.05), 임상적 문맥압 항진증 동반유무에 따른 차이는 관찰되지 않았다. Child-Pugh 분류 A, B, C에 따른 말초혈액 NO 활성도는 각각 84.9±45.5, 81.9±53.2, 86.4±39.8 μmol/L로 각 분류 간의 차이는 관찰할 수 없었으며, albumin, bilirubin, prothrombin time 등 생화학적 검사에 따른 NO 활성도의 차이도 관찰되지 않았다. 결론 : 간경변증 환자의 말초혈액에서 NO 활성도는 정상 대조군에 비해 증가되었으나 임상적 문맥압 항진증이나 잔여 간기능의 정도는 반영하지 못하였다. 향후 NO 활성도와 혈관 리모델링 및 맥관형성과 같은 과역동 혈액순환, 문맥압 항진증 및 잔여 간기능과의 정확한 상관관계의 분석을 위해서는 말초 혈액순환에서 보다는 간내 혈액순환이나 문맥 및 내장 혈액순환에서의 직접적인 NO 활성도 측정이 도움이 될 것으로 생각된다.

Keywords

References

  1. Langer DA, Shah VH. Nitric oxide and portal hypertension: interface of vasoreactivity and angiogenesis. J Hepatol 44:209-216, 2006 https://doi.org/10.1016/j.jhep.2005.10.004
  2. Albanis E, Safadi R, Friedman SL. Treatment of hepatic fibrosis: almost there. Curr Gastroenterol Rep 5:48-56, 2003 https://doi.org/10.1007/s11894-003-0009-7
  3. Shah V. Cellular and molecular basis of portal hypertension. Clin Liver Dis 5:629-644, 2001 https://doi.org/10.1016/S1089-3261(05)70185-9
  4. Reichen J. Liver function and pharmacological considerations in pathogenesis and treatment of portal hypertension. Hepatology 11:1066-1078, 1990 https://doi.org/10.1002/hep.1840110625
  5. Ignarro LJ. Endothelium-derived nitric oxide: actions and properties. FASEB J 3:31-36, 1989 https://doi.org/10.1096/fasebj.3.1.2642868
  6. Bredt DS, Snyder SH. Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. Proc Natl Acad Sci U S A 87:682-685, 1990
  7. Wiest R, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology 35:478-491, 2002 https://doi.org/10.1053/jhep.2002.31432
  8. Shah V. Lyford G, Gores G, Farrugia G. Nitric oxide in gastrointestinal health and disease. Gastroenterology 126:903-913, 2004 https://doi.org/10.1053/j.gastro.2003.11.046
  9. Rockey D. The cellular pathogenesis of portal hypertension: stellate cell contractility, endothelin, and nitric oxide. Hepatology 25:2-5, 1997 https://doi.org/10.1002/hep.510250102
  10. Kawada N, Tran-Thi TA, Klein H, Decker K. The contraction of hepatic stellate (Ito) cells stimulated with vasoactive substances: possible involvement of endothelin 1 and nitric oxide in the regulation of the sinusoidal tonus. Eur J Biochem 213:815-823, 1993 https://doi.org/10.1111/j.1432-1033.1993.tb17824.x
  11. Rockey DC, Chung JJ. Inducible nitric oxide synthase in rat hepatic lipocytes and the effect of nitric oxide on lipocyte contractility. J Clin Invest 95:1199-1206, 1995 https://doi.org/10.1172/JCI117769
  12. Zimmermann H, Kurzen P, Klossner W, Renner EL, Marti U. Decreased constitutive hepatic nitric oxide synthase expression in secondary biliary fibrosis and its changes after Roux-en-Y choledocho-jejunostomy in the rat. J Hepatol 25:567-573, 1996 https://doi.org/10.1016/S0168-8278(96)80218-2
  13. Rockey DC, Chung JJ. Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension. Gastroenterology 114:344-351, 1998 https://doi.org/10.1016/S0016-5085(98)70487-1
  14. Bomzon A, Blendis LM. The nitric oxide hypothesis and the hyperdynamic circulation in cirrhosis. Hepatology 20:1343-1350, 1994 https://doi.org/10.1002/hep.1840200535
  15. Sogni P, Moreau R, Gadano A, Lebrec D. The role of nitric oxide in the hyperdynamic circulatory syndrome associated with portal hypertension. J Hepatol 23:218-224, 1995 https://doi.org/10.1016/0168-8278(95)80339-4
  16. Curgunlu A, Vural P, Canbaz M, Erten N, Karan MA, Tascioglu C. Plasma nitrate/nitrite and endothelin-1 in patients with liver cirrhosis. J Clin Lab Anal 19:177-181, 2005 https://doi.org/10.1002/jcla.20074
  17. Sandhu BS, Sanyal AJ. Management of ascites in cirrhosis. Clin Liver Dis 9:715-732, 2005 https://doi.org/10.1016/j.cld.2005.07.008
  18. Arroyo V. Pathophysiology, diagnosis and treatment of ascites in cirrhosis. Ann Hepatol 1:72-79, 2002
  19. Gines P, Cardenas A, Arroyo V, Rodes J. Management of cirrhosis and ascites. N Engl J Med 350:1646-1654, 2004 https://doi.org/10.1056/NEJMra035021
  20. Ohara N, Futagawa S, Watanabe S, Fukasawa M, Takamori S. Clinical investigation of endothelin-1 and nitric oxide in patients with portal hypertension focusing on plasma levels and immunohistological staining of liver tissues. Hepatol Res 21:40-54, 2001 https://doi.org/10.1016/S1386-6346(01)00077-8
  21. Sarela AI, Mihaimeed FM, Batten JJ, Davidson BR, Mathie RT. Hepatic and splanchnic nitric oxide activity in patients with cirrhosis. Gut 44:749-753, 1999 https://doi.org/10.1136/gut.44.5.749
  22. Huang PL, Huang Z, Mashimo H, Bloch KD, Moskowitz MA, Bevan JA, Fishman MC. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 377:239-242, 1995 https://doi.org/10.1038/377239a0
  23. Arkenau HT, Stichtenoth DO, Frolich JC, Manns MP, Boker KH. Elevated nitric oxide levels in patients with chronic liver disease and cirrhosis correlate with disease stage and parameters of hyperdynamic circulation. Z Gastroenterol 40:907-913, 2002. https://doi.org/10.1055/s-2002-35413
  24. Lowenstein CJ, Padalko E. iNOS (NOS2) at a glance. J Cell Sci 117:2865-2867, 2004 https://doi.org/10.1242/jcs.01166
  25. Mungrue IN, Bredt DS. nNOS at a glance: implications for brain and brawn. J Cell Sci 117:2627-2629, 2004 https://doi.org/10.1242/jcs.01187
  26. Song IH, Choi J, Chin YJ, Lim CY, Kim JW, Roe IH. Expression of inducible nitric oxide synthase mRNA in esophageal varix and congestive gastropathy secondary to portal hypertension. Korean J Gastroenterol 32:137-146, 1998
  27. Fleming I. Busse R. Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am J Physiol Regul Integr Comp Physiol 284:R1-R12, 2003 https://doi.org/10.1152/ajpregu.00323.2002
  28. Kawanaka H, Jones MK, Szabo IL, Baatar D, Pai R, Tsugawa K, Sugimachi K, Sarfeh IJ, Tarnawski AS. Activation of eNOS in rat portal hypertensive gastric mucosa is mediated by TNF-alpha via the PI 3-kinase-Akt signaling pathway. Hepatology 35:393-402, 2002 https://doi.org/10.1053/jhep.2002.30958
  29. Wiest R, Cadelina G, Milstien S, McCuskey RS, Garcia-Tsao G, Groszmann RJ. Bacterial translocation up-regulates GTP-cyclohydrolase I in mesenteric vasculature of cirrhotic rats. Hepatology 38:1508-1515, 2003 https://doi.org/10.1016/j.hep.2003.09.039
  30. Fernandez M, Vizzutti F, Garcia-Pagan JC, Rodes J, Bosch J. Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice. Gastroenterology 126:886-894, 2004 https://doi.org/10.1053/j.gastro.2003.12.012